Drugs / Loxoprofen

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT02602353 Oct → Dec 2015 Lead Chemical Co., Ltd. Completed No outcome recorded
Phase 2 NCT01922466 Jul 2013 → Mar 2014 Kyunghee University Medical Center Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02831569 Jul → Oct 2016 Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT00141154 Oct 2004 → ? Viatris Inc. Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03800797 May → Dec 2015 ankylosing spondylitis Sun Yat-sen University Completed No outcome recorded
Phase not applicable5 trials
NCT07591220 Jun 2026 → Dec 2027 expected Beijing Tiantan Hospital Not yet recruiting No outcome recorded
NCT07591207 Jun 2026 → Dec 2027 expected gallbladder disorder Beijing Tiantan Hospital Recruiting No outcome recorded
NCT07378059 Dec 2025 → Sep 2027 expected herpes zoster Beijing Tiantan Hospital Recruiting No outcome recorded
NCT04611685 Oct 2020 → Oct 2021 pituitary gland adenoma Peking Union Medical College Hospital Unknown No outcome recorded
NCT02983747 Nov 2019 → Dec 2022 Shanghai Changzheng Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 9 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00676117 Comparator Apr → Jul 2008 AstraZeneca Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06047483 Comparator Oct → Dec 2023 Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 2 NCT02467504 Comparator Jul 2015 → Jan 2017 rheumatoid arthritis Peking University People's Hospital Completed No outcome recorded
Phase 2 NCT01491321 Background Apr 2011 → Mar 2012 chronic pain syndrome Kyunghee University Medical Center Unknown No outcome recorded
Phase 33 trials
Phase 3 NCT03386149 Comparator Dec 2017 → Dec 2019 lumbar disk disease Kyunghee University Medical Center Completed No outcome recorded
Phase 3 NCT02616068 Comparator Oct 2015 → Dec 2016 Daiichi Sankyo Completed No outcome recorded
Phase 3 NCT01779271 Comparator Jan 2013 → Mar 2016 respiratory tract infectious disorder Daewon Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00994461 Comparator Nov 2009 → Apr 2010 Viatris Inc. Completed No outcome recorded
Phase not applicable1 trial
NCT02384928 Comparator Sep 2015 → Jan 2017 lumbar disk disease, sciatica Jaseng Medical Foundation Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2010-10-05 Daiichi Sankyo Daiichi Sankyo to Launch Percutaneous Analgesic and Anti-Inflammatory Drug Loxonin(R) Gel 1% in Japan daiichisankyo.com
2008-07-09 Daiichi Sankyo Percutaneous Absorption-type Analgesic and Anti-Inflammatory Drug Loxonin(R) Tape 50mg/100mg Launched daiichisankyo.com
2008-03-12 Daiichi Sankyo The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg Receives Approval for Manufacture and Marketing daiichisankyo.com
2006-05-22 Daiichi Sankyo Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg to Go on Sale daiichisankyo.com
2006-01-23 Daiichi Sankyo The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture daiichisankyo.com

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 22 sources stand behind the page.

FieldValueCited text
Known as loxoprofen Loxoprofen (po.) for routine use during the first 3 postop. days.” NCT04611685
14

“Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)” NCT03386149

loxoprofen sodium (Drug class: NSAIDs)” NCT02384928

NCT00141154

NCT01922466

NCT06047483

NCT07378059

NCT02602353

NCT00994461

NCT07591220

NCT01779271

NCT01491321

NCT00676117

NCT02467504

NCT07591207

Known as Loxonin Loxonin® (loxoprofen sodium 60 mg - Daiichi-Sankyo - control group)” NCT02616068
Known as Loxonine tab. “Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)” NCT03386149
Known as LOXONNIN “Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .),P.O., 60mg, three times a day” NCT02983747
Known as Loxoprofen acid ChEMBL registry synonym — accepted as the source's own label CHEMBL19299
Known as loxoprofen patch “Therefore, we aimed at evaluating the efficacy and safety of loxoprofen patch (LX-P) in the treatment of patients with posttraumatic pain.” PMID 30839430 Jul 2019
Known as loxoprofen sodium “Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind,...” PMID 30839430 Jul 2019
7

“Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)” NCT03386149

loxoprofen sodium (loxoprofen), a pro-drug in the propionic acid class of nonselective NSAIDs” PMID 23216412 Dec 2012

loxoprofen sodium (Drug class: NSAIDs)” NCT02384928

NCT02616068

NCT02831569

NCT02983747

NCT03800797

Known as loxoprofen tablet “Patients were assigned to active LX-P or to loxoprofen tablet (LX-T), and pain intensity was measured based on a visual analog scale score variation after 7 days of treatment.” PMID 30839430 Jul 2019
Known as Loxoprofene ChEMBL registry synonym — accepted as the source's own label CHEMBL19299
Known as Loxoprofeno ChEMBL registry synonym — accepted as the source's own label CHEMBL19299
Known as LX-P “Therefore, we aimed at evaluating the efficacy and safety of loxoprofen patch (LX-P) in the treatment of patients with posttraumatic pain.” PMID 30839430 Jul 2019
Known as LX-T “Patients were assigned to active LX-P or to loxoprofen tablet (LX-T), and pain intensity was measured based on a visual analog scale score variation after 7 days of treatment.” PMID 30839430 Jul 2019
Modality Small molecule “loxoprofen sodium (loxoprofen), a pro-drug in the propionic acid class of nonselective NSAIDs” PMID 23216412 Dec 2012
Route Oral “repeated oral administration” NCT00676117